Glycoprotein IIb-IIIa Antagonists in Non-ST Elevation Acute Coronary Syndromes and Percutaneous Interventions: From Pharmacology to Individual Patient's Therapy. Part 1: The Evidence of Benefit

Journal of Cardiovascular Pharmacology

Volumn 43, Issue 3, 2004, Pages 325-332

  Zimarino, Marco ^a   De Caterina, Raffaele ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Antiplatelet agents; Percutaneous coronary interventions; Unstable coronary syndromes

Indexed keywords

ABCIXIMAB; CREATINE KINASE MB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MUSCLE NECROSIS; NON ST ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; ROTATIONAL ATHERECTOMY;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; COMORBIDITY; CORONARY DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; STENTS; TYROSINE;

EID: 1442301520     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200403000-00001     Document Type: Review

References (62)

1. Hines RO. Integrins: a family of cell surface receptors. Cell. 1987;48: 549-554.
2. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553-1559.
3. Coller BS, Peerschke EI, Scudder LE, et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 1983;72:325-338.
4. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists: What are the relevant issues concerning their pharmacology and clinical use? Circulation. 1999:100.
5. Fox KAA, Goodman SG, Klein W, et al. Investigators AAftG. Management of acute coronary syndromes: Variations in practice and outcome. Findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2002;23:1977-1989.
6. Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin: The Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J. 2002; 23:1190-1201.
7. Fox AA, Goodman SG, Anderson FA, et al.. From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. Eur Heart J. 2003:1414-1424.
8. Peterson ED, Pollack CV, Roe MT. for the National Registry of Myocardial Infarction (NRMI) 4 Investigators. Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction. J Am Coll Cardiol. 2003;42:45-53.
9. Coller BS, Scudder LE, Beer J, et al. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann N Y Acad Sci. 1991; 614:193-213.
10. Phillips DR, RMS. Clinical pharmacology of eptifibatide. Am J Cardial. 1997;80:11B-20B.
11. Lynch JJ Jr, Cook JJ, Sitko GR, et al. Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383. J Pharmacol Exp Ther. 1995;272:20-32.
12. Kouns WC, Kirchhofer D, Hadvary P, et al. Reversible conformational changes induced in glycoprotein IIb/IIIa by a potent and selective peptidomimetic inhibitor. Blood. 1992;80:2539-2547.
13. Coller BS. Potential nonglycoprotein IIb/IIIa effects of abciximab. Am Heart J. 1999;138:S1-S5.
14. Aymong ED, Curtis MJ, Youssef M, et al. Abciximab attenuates coronary microvascular endothelial dysfunction after coronary stenting. Circulation. 2002;105:2981-2985.
15. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
16. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularisation. N Engl J Med. 1997;336:1689-1696.
17. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 1997;349:1429-1435.
18. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet. 1998;352:87-92.
19. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet. 1997;349:1422-1428.
20. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000;356:2037-2044.
21. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation. 1997;96:1445-1453.
22. Chew DP, Moliterno DJ. A critical appraisal of platelet glycoprotein IIb/IIIa inhibition. J Am Coll Cardiol. 2000;36:2028-2035.
23. Anderson KM, Califf RM, Stone GW, et al. Long-term mortality benefit with Abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2001;37:2059-2065.
24. Ellis SG, Lincoff AM, Miller D. Investigators. eaftEaE. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC). Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade (EPILOG). J Am Coll Cardiol. 1998;32:1619-1623.
25. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial Infarction Redefined-A Consensus Document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J. 2000;21:1502-1513.
26. Wong GC, Morrow DA, Murphy S, et al. Group ftT-TS. Elevations in Troponin T and I Are Associated With Abnormal Tissue Level Perfusion A TACTICS-TIMI 18 Substudy. Circulation. 2002;106:202-207.
27. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241-251.
28. Prati F, Pawlowski T, Gil R, et al. Stenting of culprit lesions in unstable angina leads to a marked reduction in plaque burden. A major role of plaque embolisation? A serial intravascular ultrasound study. Circulation. 2003;107:2320-2325.
29. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 2000;101:570-580.
30. Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol. 2001;37:2239i-lxvi.
31. Ellis SG, Chew D, Chan A, et al. Death following creatine kinase-MB elevation after coronary intervention identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation. 2002;106:1205-1210.
32. Rankin JM, Spinelli JJ, Carere RG, et al. Improved clinical outcome after widespread use of coronary artery stenting in Canada. N Engl J Med. 1999;341:1957-1965.
33. Brener SJ, Ellis SG, Schneider J, et al. Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J. 2002;23:869-876.
34. Topol EJ, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 1999;354:2019-2024.
35. Cutlip DE, Leon MB, Ho KKL, et al. Investigators ftSA-tRS. Acute and nine-month clinical outcomes after "suboptimal" coronary stenting. Results from the STent Anti-thrombotic Regimen Study (STARS) Registry. J Am Coll Cardiol. 1999;34:698-706.
36. Lincoff AM. Important triad in cardiovascular medicine. Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade. Circulation. 2003;107:1556-1559.
37. Marso SP, Lincoff M, Ellis SG, et al. for the EPISTENT Investigators. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus. Results of the EPISTENT Diabetic Substudy. Crculation. 1999;100:2477-2484.
38. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation. 2001;104:2767-2771.
39. McCullough PA. Why is chronic kidney disease the 'spoiler' for cardiovascular outcomes? J Am Coll Cardiol. 2003;41:725-728.
40. Freeman RV, Mehta RH, Al Badar W, et al. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of Glycoprotein IIb-IIIa inhibitors. J Am Coll Cardiol. 2003;41:718-724.
41. Ellis SG, Guetta V, Miller D, et al. Relation between lesion characteristics and risk with percutaneous intervention in the stent and glycoprotein IIb/IIIa era. Circulation. 1999;100:1971-1976.
42. Zhao XQ, Theroux P, Snapinn SM, et al. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial. Circulation. 1999;100:1609-1615.
43. Heeschen C, van den Brand MJ, Hamm CW, for the CAPTURE investigators. Angiographic findings in patients with refractory unstable angina according to Troponin T status. Circulation. 1999;104:1509-1514.
44. Zimarino M, Corcos T, Favereau X, et al. Rotational coronary atherectomy with adjunctive balloon angioplasty: evaluation of mechanisms by quantitative angiographic analysis. Am Heart J. 1997;133:203-209.
45. Williams MS, Coller BS, Vaananen HJ, et al. Activation of platelets in platelet-rich plasma by rotablation is speed-dependent and can be inhibited by abciximab. Circulation. 1998;98:742-748.
46. Koch KC, vom Dahl J, Kleinhans E, et al. Influence of a platelet GPIIb/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy. J Am Coll Cardiol. 1999;33:998-1004.
47. Baim DS, Wahr D, George B, et al. on behalf of the Saphenous vein graft Angioplasty Free of Emboli Randomized (SAFER) Trial Investigators. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. 2002;105:1285-1290.
48. Roffi M, Mukherjee D, Chew, et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts. Circulation. 2002;106:3063-3067.
49. Calvin JE, Klein LW, VandenBerg BJ, et al. Risk stratification in unstable angina. Prospective validation of the Braunwald classification. JAMA. 1995;273:136-141.
50. The PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338: 1498-1505.
51. The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms. N Engl J Med. 1998;338:1488-1497.
52. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med. 1998;339:436-443.
53. The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation. 1998;97:2386-2395.
54. Boersma E, Akkerhuis KM, Théroux P, et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation. 2000;100:2045-2048.
55. Hamm CW, Heeschen C, Goldmann B, et al. for the c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med. 1999;340:1623-1629.
56. Heeschen C, Hamm CW, Goldmann B, et al. for the PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet. 1999; 354:1757-1762.
57. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000;284:835-842.
58. Morrow DA, Antman EM, Snapinn S, et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. Eur Heart J. 2002;23:223-229.
59. The GUSTO-IV ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001;357:1915-1924.
60. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA. 1999; 281:707-713.
61. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189-198.
62. The PARAGON-B investigators. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation. 2002;105:316-321.